Compounded GLP-1s
4 articles on Compounded GLP-1s, written by Shotlee and medically reviewed for clinical accuracy.
Obesity Drug Coverage Restrictions Force Patients to Pivot
Tight insurance restrictions on obesity drugs are turning doctors into financial advisors and patients into strategists. With coverage limits on Zepbound favoring Wegovy, many are pivoting to compounded alternatives at $300/month versus $450 for brand names. Explore the real challenges and solutions from experts and patients.
5 min read
Hims & Hers Stock: Costly Wegovy Deal Challenges
Hims & Hers has resolved its dispute with Novo Nordisk, shifting to official weight loss drugs like Wegovy over controversial compounded GLP-1 alternatives. This brings legal clarity but slams profitability with higher costs and a cautious Q1 2026 revenue outlook of $600-625 million. With 2.5 million subscribers, can the stock rebound amid debt and investigations?
4 min read
Eli Lilly Warns of Counterfeit Mounjaro, Zepbound Risks from Impurities
Eli Lilly, maker of Mounjaro and Zepbound, has discovered critical impurities in counterfeit tirzepatide versions mixed with vitamin B12. These compounded drugs pose unknown risks due to chemical reactions and lack of FDA oversight. With one in eight Americans using GLP-1s, experts urge sticking to approved medications.
5 min read
The Himsification of Medicine: Super Bowl Ad & Semaglutide Clash
Hims & Hers made waves with a Super Bowl ad promoting preventive care through tailored prescriptions and peptides for everyday Americans. But announcing compounded oral semaglutide triggered an FDA investigation and a swift lawsuit from Novo Nordisk. The quick settlement highlights battles over GLP-1 access and drug pricing.
4 min read